ATE495736T1 - Verwendung von derivaten der 2-oxothiazolidin-4- corbonsäure als prä-abschuppungsmittel - Google Patents

Verwendung von derivaten der 2-oxothiazolidin-4- corbonsäure als prä-abschuppungsmittel

Info

Publication number
ATE495736T1
ATE495736T1 AT01996360T AT01996360T ATE495736T1 AT E495736 T1 ATE495736 T1 AT E495736T1 AT 01996360 T AT01996360 T AT 01996360T AT 01996360 T AT01996360 T AT 01996360T AT E495736 T1 ATE495736 T1 AT E495736T1
Authority
AT
Austria
Prior art keywords
oxothiazolidine
corbonic
depender
derivatives
acid
Prior art date
Application number
AT01996360T
Other languages
English (en)
Inventor
Jean-Baptiste Galey
Dominique Bernard
Lucie Simonetti
Original Assignee
Oreal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oreal filed Critical Oreal
Application granted granted Critical
Publication of ATE495736T1 publication Critical patent/ATE495736T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
    • A61K2800/28—Rubbing or scrubbing compositions; Peeling or abrasive compositions; Containing exfoliants
AT01996360T 2000-11-17 2001-11-12 Verwendung von derivaten der 2-oxothiazolidin-4- corbonsäure als prä-abschuppungsmittel ATE495736T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0014865A FR2816838B1 (fr) 2000-11-17 2000-11-17 Utilisation de derives de l'acide 2-oxothiazolidine- 4-carboxylique comme agents prodesquamants
PCT/FR2001/003523 WO2002039976A1 (fr) 2000-11-17 2001-11-12 Utilisation de derives de l'acide 2-oxothiazolidine 4-carboxylique comme agents prodesquamants

Publications (1)

Publication Number Publication Date
ATE495736T1 true ATE495736T1 (de) 2011-02-15

Family

ID=8856595

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01996360T ATE495736T1 (de) 2000-11-17 2001-11-12 Verwendung von derivaten der 2-oxothiazolidin-4- corbonsäure als prä-abschuppungsmittel

Country Status (9)

Country Link
US (3) US20040006115A1 (de)
EP (1) EP1337234B1 (de)
JP (1) JP4072433B2 (de)
AT (1) ATE495736T1 (de)
AU (1) AU2002223058A1 (de)
DE (1) DE60143906D1 (de)
ES (1) ES2360204T3 (de)
FR (1) FR2816838B1 (de)
WO (1) WO2002039976A1 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040161392A1 (en) * 2003-02-19 2004-08-19 L'oreal S.A. Skin peeling composition and method
FR2888494B1 (fr) * 2005-07-13 2014-03-14 Oreal Utilisation de composes d'uree pour favoriser la desquamation
AU2006332945C1 (en) 2005-12-23 2013-02-28 Wyeth Modified lysine-mimetic compounds
EP2074087A2 (de) * 2006-12-21 2009-07-01 Wyeth Synthese von pyrrolidinverbindungen
FR2921257B1 (fr) 2007-09-21 2009-11-06 Exsymol Sa Utilisation topique de derives thiazolidines contre les consequences du stress oxydatif de la peau
ES2336995B1 (es) 2008-10-13 2011-02-09 Lipotec, S.A. Composicion cosmetica o dermofarmaceutica para el cuidado de la piel,cuero cabelludo y uñas.
EP2578203B1 (de) 2010-05-28 2015-04-01 Ajinomoto Co., Inc. Cysteinderivat
ES2885523T3 (es) 2011-11-23 2021-12-14 Therapeuticsmd Inc Formulaciones y terapias de reposición hormonal de combinación naturales
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
JP5994790B2 (ja) * 2011-11-30 2016-09-21 味の素株式会社 美白化粧料
JP5979155B2 (ja) * 2011-11-30 2016-08-24 味の素株式会社 システイン誘導体およびアルコールを含有する化粧料
JP5994789B2 (ja) * 2011-11-30 2016-09-21 味の素株式会社 シワ防止化粧料
WO2013081192A1 (ja) * 2011-11-30 2013-06-06 味の素株式会社 システイン誘導体および界面活性剤を含有する化粧料
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
IN2013CH02665A (de) * 2013-06-19 2015-06-19 Kop Res Ct Pvt Ltd
AU2015264003A1 (en) 2014-05-22 2016-11-17 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
WO2017173071A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
DK3618847T3 (da) 2017-05-05 2021-05-25 Boston Medical Ct Corp GAP-junction-modulatorer af intercellulær kommunikation og deres anvendelse til behandling af diabetisk øjensygdom
EP3727314B1 (de) * 2017-12-20 2021-10-13 Unilever IP Holdings B.V. Deodorierende zusammensetzungen

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4806525A (en) * 1987-06-18 1989-02-21 Mavi S.R.L. Formulation comprising gelatin and glycine for treating the dryness of skin
US5208249A (en) * 1992-08-20 1993-05-04 Clintec Nutrition Co. Method for stimulating intracellular synthesis of glutathione using esters of L-2-oxothiazolidine-4-carboxylate
AU7596994A (en) * 1993-11-01 1995-05-18 Free Radical Sciences, Inc. Methods and compositions for retarding the aging process
US5681852A (en) * 1993-11-12 1997-10-28 The Procter & Gamble Company Desquamation compositions
DE4444238A1 (de) * 1994-12-13 1996-06-20 Beiersdorf Ag Kosmetische oder dermatologische Wirkstoffkombinationen aus Zimtsäurederivaten und Flavonglycosiden
ES2169247T3 (es) * 1995-05-26 2002-07-01 Unilever Nv Regimen de tratamiento para la piel.
FR2742658B1 (fr) * 1995-12-22 1998-01-30 Oreal Utilisation de la procysteine comme agent depigmentant
FR2742750B1 (fr) * 1995-12-22 1998-01-30 Oreal Nouveaux derives de l'acide l-2-oxothiazolidine 4-carboxylique et leur utilisation pour le soin de la peau
US6063389A (en) * 1995-12-22 2000-05-16 L'oreal Composition for depigmenting or bleaching mammalian skin containing L-2-oxothiazolidine-4-carboxylic acid and a polyol
FR2751331A1 (fr) * 1996-07-18 1998-01-23 Oreal Nouveau derive de l'acide kojique et son utilisation comme agent depigmentant
EP0852949A3 (de) * 1997-03-31 1999-08-04 Shiseido Company Limited Verwendung von Alpha-Aminosäuren zur Förderung des desmosomalen Abbaues oder der Abschuppung der Hornschicht
FR2767833B1 (fr) * 1997-08-29 2001-03-02 Oreal Polypeptide isole de l'epiderme et son utilisation
FR2773323B1 (fr) * 1998-01-05 2000-02-11 Oreal Composition contenant une association de procysteine et de polyol
US5989527A (en) * 1998-01-26 1999-11-23 Inolex Investment Corporation Compositions and methods for improving the performance of chemical exfoliating agents, sunless tanning agents, skin lightening agents and insect repellents
FR2790953B1 (fr) * 1999-03-19 2002-08-09 Oreal Composition a phase aqueuse continue renfermant de l'acide l-2-oxothiazolidine 4-carboxylique

Also Published As

Publication number Publication date
US20070232574A1 (en) 2007-10-04
WO2002039976A1 (fr) 2002-05-23
FR2816838B1 (fr) 2004-12-03
EP1337234B1 (de) 2011-01-19
DE60143906D1 (de) 2011-03-03
FR2816838A1 (fr) 2002-05-24
JP4072433B2 (ja) 2008-04-09
JP2004517063A (ja) 2004-06-10
US20100179200A1 (en) 2010-07-15
ES2360204T3 (es) 2011-06-01
EP1337234A1 (de) 2003-08-27
AU2002223058A1 (en) 2002-05-27
US20040006115A1 (en) 2004-01-08

Similar Documents

Publication Publication Date Title
ATE495736T1 (de) Verwendung von derivaten der 2-oxothiazolidin-4- corbonsäure als prä-abschuppungsmittel
DE69910831D1 (de) Epothilonderivate und ihre verwendung als antitumormittel
NO20054476L (no) Forbindelser for behandling av smerte
EE9900217A (et) Sulfiinhappe derivaadid, nende valmistamine ja kasutamine
ATE368034T1 (de) Heteroarylsubstituierte biphenylderivate als inhibitoren von p38-kinase
DK1686119T3 (da) Pyrimidin-5-on-derivater som LDL-PLA2 inhibitorer
BR9806752A (pt) Ftalazinonas.
BR0114045A (pt) Poliarilcarboxamidas úteis como agentes redutores de lipìdeos
BR0209149A (pt) Ftalazinonas
ATE249220T1 (de) Verwendung von piperin und derivate davon zur behandlung von hautpigmentierungstörungen und hautkrebs
DE60130661D1 (de) Verwendung der 13-cis retinsäure zur behandlung von emphysemen
BR0014990A (pt) Derivados de tetrahidrotiopirano ranftalazinona como inibidores de pde4
SE9904674D0 (sv) Novel compounds
ATE288922T1 (de) Bestimmte heteroaryl substituierte thiol inhibitoren von endothelin wechselnden enzymen
ATE333457T1 (de) Zyklische gmp-spezifische phosphodiesteraseinhibitoren
ATE521331T1 (de) Verwendung von bis-resorcinyltriazinderivaten in kosmetischen oder dermatologischen zubereitungen
DE60112148T2 (de) Verwendung von (Per)fluoroetherverbindungen als Zusatzstoffe in Formulierungen zur Holzbehandlung
DE60041001D1 (de) Substituierte homopiperidylbenzimidazolanaloga als fundusrelaxantien
BR0110490B1 (pt) agentes de tingimento contendo derivados de n-heteroarilmetil-m-fenilenodiamina para fibras de queratina bem como novos derivados de n-heteroarilmetil-m-fenilenodiamina.
CY1106472T1 (el) Η χρηση των παραγωγων υδροξυπυριδονης στην επουλωση πληγων
DE502004011187D1 (de) M-diaminobenzole und deren säureaddukte sowie deren verwendung in färbemitteln
DE59803066D1 (de) Substituierte benzyloxyimino-verbindungen
DE59809344D1 (de) Disubstituierte biphenyloxazoline
DE60225530D1 (de) Phosphorylierte glyoxalase i und deren verwendung
DE60326348D1 (de) Makrozyclen zur behandlung von krebserkrankungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties